 Celcuity Inc NASDAQ: CELC has announced a clinical trial collaboration with the MD Anderson Cancer Center, Novartis AG NYSE: NVS, and Puma Biotechnology Inc NASDAQ: PUMA to conduct a Phase 2 clinical trial. The open-label Phase 2 trial will evaluate the efficacy and safety of two targeted therapies, Novartis Tabrecta, a c-Met inhibitor, and Pumas Nerlynx, a pan-HER inhibitor, in patients with previously treated metastatic HER2-negative breast cancer selected with Celcuitys CELsignia Multi-Pathway Activity Test. 